VENTYX BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.13 USD | +17.39% |
|
+8.23% | +107.69% |
Presenter SpeechCarter L. Gould (Analysts)All right. Good morning, and welcome to Day 2 of Bar...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Companyâs pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
Calendar
2024-06-04
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
5.13
USD
Average target price
10.7
USD
Spread / Average Target
+108.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +107.69% | 308M | |
| +9.83% | 118B | |
| +10.80% | 106B | |
| -10.84% | 23.4B | |
| -1.69% | 22.1B | |
| -10.23% | 18.34B | |
| -41.92% | 16.59B | |
| -15.11% | 15.97B | |
| +6.62% | 14.03B | |
| +17.53% | 11.67B |
- Stock Market
- Equities
- VTYX Stock
- News Ventyx Biosciences, Inc.
- Transcript : Ventyx Biosciences, Inc. Presents at Barclays Global Healthcare Conference, Mar-15-2023 09
